First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease

Recommendations of the American Society of Blood and Marrow Transplantation

Paul J. Martin, J. Douglas Rizzo, John R. Wingard, Karen Ballen, Peter T. Curtin, Corey Cutler, Mark R Litzow, Yago Nieto, Bipin N. Savani, Jeffrey R. Schriber, Paul J. Shaughnessy, Donna A. Wall, Paul A. Carpenter

Research output: Contribution to journalReview article

215 Citations (Scopus)

Abstract

Despite prophylaxis with immunosuppressive agents or a variety of other approaches, many patients suffer from acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation. Although consensus has emerged supporting the use of high-dose methylprednisolone or prednisone for initial treatment of aGVHD, practices differ among centers with respect to the initial glucocorticoid dose, the use of additional immunosuppressive agents, and the approach to withdrawal of treatment after initial improvement. Despite many studies, practices vary considerably with respect to the selection of agents for treatment of glucocorticoid-resistant or refractory GVHD. Investigators and clinicians have recognized the lack of progress and lamented the absence of an accepted standard of care for secondary treatment of aGVHD. The American Society of Blood and Marrow Transplantation has developed recommendations for treatment of aGVHD to be considered by care providers, based on a comprehensive and critical review of published reports. Because the literature provides little basis for a definitive guideline, this review also provides a framework for the interpretation of previous results and the design of future studies.

Original languageEnglish (US)
Pages (from-to)1150-1163
Number of pages14
JournalBiology of Blood and Marrow Transplantation
Volume18
Issue number8
DOIs
StatePublished - Aug 2012

Fingerprint

Graft vs Host Disease
Transplantation
Bone Marrow
Immunosuppressive Agents
Glucocorticoids
Cell Transplantation
Methylprednisolone
Therapeutics
Standard of Care
Prednisone
Patient Selection
Research Personnel
Guidelines

Keywords

  • Acute graft-versus-host disease
  • Hematopoietic cell transplantation
  • Treatment

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease : Recommendations of the American Society of Blood and Marrow Transplantation. / Martin, Paul J.; Rizzo, J. Douglas; Wingard, John R.; Ballen, Karen; Curtin, Peter T.; Cutler, Corey; Litzow, Mark R; Nieto, Yago; Savani, Bipin N.; Schriber, Jeffrey R.; Shaughnessy, Paul J.; Wall, Donna A.; Carpenter, Paul A.

In: Biology of Blood and Marrow Transplantation, Vol. 18, No. 8, 08.2012, p. 1150-1163.

Research output: Contribution to journalReview article

Martin, PJ, Rizzo, JD, Wingard, JR, Ballen, K, Curtin, PT, Cutler, C, Litzow, MR, Nieto, Y, Savani, BN, Schriber, JR, Shaughnessy, PJ, Wall, DA & Carpenter, PA 2012, 'First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation', Biology of Blood and Marrow Transplantation, vol. 18, no. 8, pp. 1150-1163. https://doi.org/10.1016/j.bbmt.2012.04.005
Martin, Paul J. ; Rizzo, J. Douglas ; Wingard, John R. ; Ballen, Karen ; Curtin, Peter T. ; Cutler, Corey ; Litzow, Mark R ; Nieto, Yago ; Savani, Bipin N. ; Schriber, Jeffrey R. ; Shaughnessy, Paul J. ; Wall, Donna A. ; Carpenter, Paul A. / First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease : Recommendations of the American Society of Blood and Marrow Transplantation. In: Biology of Blood and Marrow Transplantation. 2012 ; Vol. 18, No. 8. pp. 1150-1163.
@article{c1352d4f2c32463290ac26b269990de1,
title = "First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation",
abstract = "Despite prophylaxis with immunosuppressive agents or a variety of other approaches, many patients suffer from acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation. Although consensus has emerged supporting the use of high-dose methylprednisolone or prednisone for initial treatment of aGVHD, practices differ among centers with respect to the initial glucocorticoid dose, the use of additional immunosuppressive agents, and the approach to withdrawal of treatment after initial improvement. Despite many studies, practices vary considerably with respect to the selection of agents for treatment of glucocorticoid-resistant or refractory GVHD. Investigators and clinicians have recognized the lack of progress and lamented the absence of an accepted standard of care for secondary treatment of aGVHD. The American Society of Blood and Marrow Transplantation has developed recommendations for treatment of aGVHD to be considered by care providers, based on a comprehensive and critical review of published reports. Because the literature provides little basis for a definitive guideline, this review also provides a framework for the interpretation of previous results and the design of future studies.",
keywords = "Acute graft-versus-host disease, Hematopoietic cell transplantation, Treatment",
author = "Martin, {Paul J.} and Rizzo, {J. Douglas} and Wingard, {John R.} and Karen Ballen and Curtin, {Peter T.} and Corey Cutler and Litzow, {Mark R} and Yago Nieto and Savani, {Bipin N.} and Schriber, {Jeffrey R.} and Shaughnessy, {Paul J.} and Wall, {Donna A.} and Carpenter, {Paul A.}",
year = "2012",
month = "8",
doi = "10.1016/j.bbmt.2012.04.005",
language = "English (US)",
volume = "18",
pages = "1150--1163",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease

T2 - Recommendations of the American Society of Blood and Marrow Transplantation

AU - Martin, Paul J.

AU - Rizzo, J. Douglas

AU - Wingard, John R.

AU - Ballen, Karen

AU - Curtin, Peter T.

AU - Cutler, Corey

AU - Litzow, Mark R

AU - Nieto, Yago

AU - Savani, Bipin N.

AU - Schriber, Jeffrey R.

AU - Shaughnessy, Paul J.

AU - Wall, Donna A.

AU - Carpenter, Paul A.

PY - 2012/8

Y1 - 2012/8

N2 - Despite prophylaxis with immunosuppressive agents or a variety of other approaches, many patients suffer from acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation. Although consensus has emerged supporting the use of high-dose methylprednisolone or prednisone for initial treatment of aGVHD, practices differ among centers with respect to the initial glucocorticoid dose, the use of additional immunosuppressive agents, and the approach to withdrawal of treatment after initial improvement. Despite many studies, practices vary considerably with respect to the selection of agents for treatment of glucocorticoid-resistant or refractory GVHD. Investigators and clinicians have recognized the lack of progress and lamented the absence of an accepted standard of care for secondary treatment of aGVHD. The American Society of Blood and Marrow Transplantation has developed recommendations for treatment of aGVHD to be considered by care providers, based on a comprehensive and critical review of published reports. Because the literature provides little basis for a definitive guideline, this review also provides a framework for the interpretation of previous results and the design of future studies.

AB - Despite prophylaxis with immunosuppressive agents or a variety of other approaches, many patients suffer from acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation. Although consensus has emerged supporting the use of high-dose methylprednisolone or prednisone for initial treatment of aGVHD, practices differ among centers with respect to the initial glucocorticoid dose, the use of additional immunosuppressive agents, and the approach to withdrawal of treatment after initial improvement. Despite many studies, practices vary considerably with respect to the selection of agents for treatment of glucocorticoid-resistant or refractory GVHD. Investigators and clinicians have recognized the lack of progress and lamented the absence of an accepted standard of care for secondary treatment of aGVHD. The American Society of Blood and Marrow Transplantation has developed recommendations for treatment of aGVHD to be considered by care providers, based on a comprehensive and critical review of published reports. Because the literature provides little basis for a definitive guideline, this review also provides a framework for the interpretation of previous results and the design of future studies.

KW - Acute graft-versus-host disease

KW - Hematopoietic cell transplantation

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84862137300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862137300&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2012.04.005

DO - 10.1016/j.bbmt.2012.04.005

M3 - Review article

VL - 18

SP - 1150

EP - 1163

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 8

ER -